|
| | Canertinib Basic information |
| Product Name: | Canertinib | | Synonyms: | CS-152;CI-1033; PD-183805; CI1033; CI 1033; PD183805; PD 183805;CI-1033 (Canertinib, PD-183805);CI-1033(Canertinib);PD-183805;CI-1033; PD-183805;Canertinib base;Canetinib | | CAS: | 267243-28-7 | | MF: | C24H25ClFN5O3 | | MW: | 485.94 | | EINECS: | 1308068-626-2 | | Product Categories: | Inhibitors | | Mol File: | 267243-28-7.mol |  |
| | Canertinib Chemical Properties |
| Melting point | 188-190° | | Boiling point | 691.0±55.0 °C(Predicted) | | density | 1.355±0.06 g/cm3(Predicted) | | storage temp. | Inert atmosphere,Store in freezer, under -20°C | | solubility | insoluble in H2O; ≥10.1 mg/mL in EtOH; ≥12.15 mg/mL in DMSO with gentle warming | | pka | 12.09±0.43(Predicted) | | form | Yellow powder. | | CAS DataBase Reference | 267243-28-7 |
| | Canertinib Usage And Synthesis |
| Uses | Canertinib is a kind of irreversible pan-erbB tyrosine kinase inhibitor used to treat cancer.
| | Uses | CI-1033 is a potent inhibitor of EGFR and ErbB2 with IC50 of 1.5 nM and 9.0 nM, respectively. | | Uses | Antineoplastic; irreversible pan-erbB tyrosine kinase inhibitor used to treat cancer. | | Definition | ChEBI: A quinazoline compound having a 3-chloro-4-fluoroanilino group at the 4-position, a propenamido group at the 6-position, and a 3-morpholinopropoxy group at the 7-position. | | Biological Activity | canertinib (also known as ci-1033), a 3-chloro, 4-fluoro, 4-anilinoquinazoline, is an orally available, potent and irreversible pan-erbb tyrosine kinase inhibitor that inhibits egfr, her2 and her4 in vitro with the half maximal inhibition concentration ic50 of 0.8 nm, 19 nm and 7 nm respectively [1].canertinib irreversibly binds into the atp pocket within the tk domain of all erbb family members, where the acrylamide side-chain at position c6 of canertinib is brought into close proximity with cysteines of erbb members, followed by the rapid formation of a covalent bond, which permanently inactivates the catalytically active erb1, erb2 and erb4 family members and effectively inhibits erbb3-dependent signaling [2]. | | references | [1] michelle arkin, mark m. moasser. her2 directed small molecule antagonists. curr opin investig drugs. author manuscript; available in pmc 2011 february 1. published in final edited form as: curr opin investig drugs. 2008 december; 9(12): 1264–1276.
[2] calvo e, tolcher aw, hammond la, patnaik a, de bono js, eiseman ia, olson sc, lenehan pf, mccreery h, lorusso p, rowinsky ek. administration of ci-1033, an irreversible pan-erbb tyrosine kinase inhibitor, is feasible on a 7-day on, 7-day off schedule: a phase i pharmacokinetic and food effect study. clin cancer res. 2004 nov 1;10(21):7112-20. |
| | Canertinib Preparation Products And Raw materials |
|
